ARVO: Mixed Results with Investigational Uveitis Drug
An investigational therapy for uveitis outperformed placebo in one randomized clinical trial, but produced mixed results in two other studies reported here.
» Go to this activity

AAO: Genes Linked to Response in Macular Degeneration
Genes may predict response to ranibizumab (Lucentis) for patients with neovascular age-related macular degeneration, according to a genome-wide association study.
» Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.